Baseline characteristics of study population (n = 74)
| Characteristic . | Value . |
|---|---|
| Age (years) | 45 [19-83] |
| ALL subtype | |
| B-cell | 65 (88) |
| T-cell | 9 (12) |
| WBC (× 109/L) | 4.1 [0.5-309.2] |
| Bone marrow blasts (%) | 81 [24-99] |
| Karyotype | |
| Diploid | 27 (36) |
| High hyperdiploidy | 5 (7) |
| Low hypodiploidy / near triploidy | 13 (18) |
| KMT2A rearranged | 2 (3) |
| Complex | 4 (5) |
| Miscellaneous | 21 (29) |
| Insufficient metaphases | 2 (3) |
| Poor-risk cytogenetics | 19/74 (26) |
| CRLF2 overexpression by flow cytometry | 9/48 (19) |
| Ph-like ALL (CRLF2 overexpression or Ph-like fusion) | 12/53 (23) |
| TP53-mutated | 20/69 (29) |
| Frontline therapy | |
| Hyper-CVAD–based | 51 (69) |
| Hyper-CVD–based | 23 (31) |
| Characteristic . | Value . |
|---|---|
| Age (years) | 45 [19-83] |
| ALL subtype | |
| B-cell | 65 (88) |
| T-cell | 9 (12) |
| WBC (× 109/L) | 4.1 [0.5-309.2] |
| Bone marrow blasts (%) | 81 [24-99] |
| Karyotype | |
| Diploid | 27 (36) |
| High hyperdiploidy | 5 (7) |
| Low hypodiploidy / near triploidy | 13 (18) |
| KMT2A rearranged | 2 (3) |
| Complex | 4 (5) |
| Miscellaneous | 21 (29) |
| Insufficient metaphases | 2 (3) |
| Poor-risk cytogenetics | 19/74 (26) |
| CRLF2 overexpression by flow cytometry | 9/48 (19) |
| Ph-like ALL (CRLF2 overexpression or Ph-like fusion) | 12/53 (23) |
| TP53-mutated | 20/69 (29) |
| Frontline therapy | |
| Hyper-CVAD–based | 51 (69) |
| Hyper-CVD–based | 23 (31) |
Continuous variables are listed as median [range] and categorical variables as n (%) or n/N (%).
WBC, white blood cell.